CDK2 and central nervous system cancer: Studies such as those on SCN3B in glioma (Liu H. et al., 2024), CDK2 in glioma (Liu and Weng, 2022), AIMP1 in head-neck squamous cell carcinoma (Li and Liu, 2022) and CNIH4 in head and neck squamous cell carcinoma (Liu and Li, 2022) demonstrate the diverse applications of TCGA data in cancer research.